The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Advancing targeted therapies for SCLC
Sophie Cousin, MD, Institut Bergonié, Bordeaux, France, discusses the field of targeted therapies for small cell lung cancer (SCLC) and the latest targets under evaluation for SCLC. The field of targeted therapies for SCLC is still limited. Previous treatments targeting DLL3 showed toxicity and limited overall response rates. However, there is hope that new drugs may provide safer and more effective treatment options by targeting DLL3 in specific subgroups of the SCLC population. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
